Leuprorelin implant (AMW)

亮丙瑞林植入物 (AMW)

Report date: 2024/05/31 11:59:46

Base Information

Drug NameLeuprorelin implant (AMW)
Drug Alias NameLeugonStaladex
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGonadotropin-releasing hormone agonists
TargetsGonadotropin-releasing hormone
Therapy Area/IndicationsNeoplasms, Hormone-DependentProstatic Neoplasms
Global Approved IndicationsProstatic Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date2019/04/03
Country/TerritoryUnited KingdomEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAmw Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesAmdeepcha LtdAmw Gmbh
Inactive CompaniesN/A
Active IndicationsNeoplasms, Hormone-DependentProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A